MPM Tries Again To Spur Early-Stage Asian Biotech Investments
This article was originally published in PharmAsia News
Executive Summary
Even though its initial early-stage investment in an Asian biotech seven years ago has seen few copies, MPM Capital of the United States is trying again. The company has invested $20 million in Sai Advantium Pharma, a contract research outfit in India. MPM had hoped to spur investments in Asian biotechs in 2001 when it invested $48 million in Taiwan's TaiGen Biotechnology, a small-molecule drug-discovery firm. Only recently did other investment companies, such as OrbiMed Advisors, follow MPM's lead. Early-stage investments in Asia remain a rarity. (Click here for more